TEL AVIV, Israel, May 15, 2026 — Biomed Israel 2026, the premier international life science conference in Israel, and 8400 The Health Network, announced today that Starget Pharma, caVos Biotech, Protai and BAIBYS™ are the winners of the startup showcase and competition for companies developing breakthrough technologies in the life sciences. The panel of
Israeli MedTech company reaches First In Human (FIH) milestone with a fully autonomous AI and robotics-based system that selects and physically isolates ideal sperm cells for IVF (ICSI) TEL AVIV, Israel, Apr 21, 2026 — BAIBYS™, an Israeli MedTech company that has developed an autonomous micro-robotic system for sperm selection
This technological breakthrough has the potential to significantly improve success rates in fertility treatments while reducing costs and time-to-pregnancy for patients worldwide.
The AI and robotics-based system by BAIBYS™ poised to transform the IVF market.
BAIBYS™ is proud to announce that it has secured another significant grant of ~ $500,000 from the prestigious Israel Innovation Authority (IIA).
We are so proud to have been selected, again, by Calcalist to participate in their Dream Team for the Mind The Tech LONDON event.
Japanese pharmaceutical giant ROHTO joined the Israeli startup’s round as it prepares to begin sales this year. BAIBYS’ system examines sperm samples and automatically selects ideal sperm according to WHO criteria, both in terms of their motility and morphology.
We are delighted to announce that BAIBYS™ Fertility has attained ISO 13485:2016 certification, a testament to our unwavering commitment to quality and safety in the medical device industry.
BAIBYS™ Fertility Ltd., a pioneer in AI-powered micro-robotics for IVF, today announced a strategic investment from ROHTO Pharmaceutical Co., Ltd. (4527:Tokyo).
We’re pleased to announce that BAIBYS™ has advanced to the finals of the EY’s annual “THE PITCH” competition. This is a significant vote of confidence for BAIBYS™ Fertility.